Boehringer Ingelheim's fifth-place finish via Nice metrics stands in contrast to the Competitive Strategy Leadership Award 2011 in the European Biopharmaceutical Contract Manufacturing Market that it received from Frost & Sullivan recently. A big part of the F&S rating is weighted toward the 19 DNA-derived biopharmaceuticals that B-I has ushered to market on behalf of such companies as Amgen, Pfizer, MedImmune, Bayer Health Care and Merck Serono. R&D pipeline is a big factor, too, says research analyst Aiswariya Chidambaram.
F&S rating criteria include such metrics as leverage of competitive intelligence, execution of competitive strategy and impact on market share, so the ranking of any CMO is bound to differ between F&S and Nice Insight.
"The biggest competitive assets of B-I include its strong R&D portfolio with a well-defined in-house biologics pipeline spanning key therapeutic areas and the proprietary technologies (both in-house and acquired) for the development of mammalian and microbial contract manufacturing," Chidambaram said via email. In other words, being attached to a bona fide drugmaker has spillover advantages for the CMO arm. B-I, in fact, just announced a dedicated focus on biosimilars, benefits of which will surely find their way to the CMO.
Nice gives Boehringer Ingelheim a 76% Q3 CP and 59% CA.